Use and Interpretation of Enteropathogen Multiplex Nucleic Acid Amplification Tests in Patients With Suspected Infectious Diarrhea

Abstract: Acute diarrheal illness due to gastrointestinal infection is a significant cause of morbidity and mortality in the United States and around the world. Determining […]

Gastro-Hep News

US Food and Drug Administration Approves Infliximab Biosimilar On December 14, 2017, the US Food and Drug Administration (FDA) approved the infliximab (Remicade, Janssen) biosimilar infliximab-qbtx […]

Highlights in Clostridium difficile Infection From the World Congress of Gastroenterology at ACG 2017

October 13-18, 2017 • Orlando, Florida Severe Refractory Clostridium difficile Infection Successfully Treated With Combination of Fidaxomicin, Vancomycin, and Fecal Microbiota Transplantation The combination of […]

Fecal Microbiota Transplantation: From Clostridium difficile to Inflammatory Bowel Disease

Abstract: Fecal microbiota transplantation (FMT) has evolved from a case report in the medical literature to the basis of major innovations in the treatment of […]

Evidence-Based Approach to Clostridium difficile Infection

G&H How common is Clostridium difficile infection in the United States? SJ In 2009, the Centers for Disease Control and Prevention (CDC) started active surveillance […]

Gastro-Hep News

Committee for Medicinal Products for Human Use Votes for 8-Week Treatment Option for Hepatitis C Virus Infection On February 28, 2017, the Committee for Medicinal Products […]

Management of Clostridium difficile Infection

Gastroenterology & Hepatology October 2016, Volume 12, Issue 10 Layth S. Al-Jashaami, MD, and Herbert L. DuPont, MD Dr Al-Jashaami is a clinical assistant professor at […]